DALLAS–(BUSINESS WIRE)–Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company
advancing first-in-class oral medicines for cancer and other serious
conditions, announced that Timothy P. Coughlin, former Chief Financial
Officer of Neurocrine Biosciences, Inc., and Thilo Schroeder, Ph.D.,
Partner at Nextech Invest, Ltd. and former Peloton Board Observer, have
been appointed to its Board of Directors. Steve Winick, J.D., Managing
Director of Topspin Partners, who has been a director since 2016, has
resigned from the Board.
“We thank Steve for his diligent service and are pleased to welcome
these two distinguished leaders to our Board of Directors,” said John A.
Josey, Ph.D., Peloton’s Chief Executive Officer. “Tim has been
instrumental to the success of a high-growth clinical-stage organization
and its transition to a commercial-stage company with successful FDA
approvals in recent years. He brings substantive executive management
experience in financial functions as well as healthcare expertise.
Thilo, who has a deep understanding of our company and programs from his
years as a Board Observer, brings considerable scientific and business
acumen as an oncology company investor.”
Timothy P. Coughlin was with Neurocrine Biosciences, Inc. from 2002 to
2018 and began serving as their Chief Financial Officer in 2006. Prior
to joining Neurocrine, Mr. Coughlin served as Vice President, Financial
Services at Catholic Health Initiatives, a nationwide integrated
healthcare delivery system. From 1989 to 1999, Mr. Coughlin was a Senior
Manager in the Health Sciences practice of Ernst & Young LLP and its
predecessors. He currently serves on the Board of Directors of Fate
Therapeutics, aTyr Pharma and Retrophin. Mr. Coughlin holds a master’s
degree in international business from San Diego State University and a
bachelor’s degree in accounting from Temple University. Mr. Coughlin is
a certified public accountant in both California and Pennsylvania.
Thilo Schroeder, Ph.D. is a Partner at Nextech Invest Ltd., a global
venture fund focused on investing in leading oncology companies. He
joined Nextech Invest in 2012. Dr. Schroeder currently serves as board
member of Revolution Medicines, IDEAYA Bioscience and ImaginAb, and
observer of Black Diamond Therapeutics. He is a prior board member of
Blueprint Medicines and board observer of Tracon Pharmaceuticals. He
holds a Ph.D. in biochemistry from the University of Zurich in
Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de
Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the
Technical University of Darmstadt in Germany.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage biopharmaceutical company
focused on translating novel scientific insights into first-in-class
medicines for patients with cancer and other debilitating or
life-threatening conditions. The company’s lead development program is
evaluating a small-molecule inhibitor of hypoxia-inducible factor-2α
(HIF-2α), a transcription factor implicated in the development and
progression of clear cell renal cell carcinoma and a variety of other
disorders. HIF-2α was previously thought to be intractable using small
molecules. To learn more about Peloton Therapeutics, visit http://www.pelotontherapeutics.com.
Contacts
Alan Musso
Chief Financial Officer
Phone: +1 (972) 629-4070
alan.musso@pelotontx.com
Mike Beyer
Sam Brown Inc.
Phone: +1 (312) 961-2502
mikebeyer@sambrown.com